Policy

Policy is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics that target RNA-binding proteins (RBPs). By leveraging a proprietary platform to identify and modulate specific RBP-RNA interactions, the company aims to address high-value targets in oncology and rare genetic diseases that were previously considered undruggable. Policy's approach focuses on the post-transcriptional regulation of gene expression, offering a unique mechanism to control disease-driving proteins. The company is currently advancing a pipeline of internal programs while exploring strategic partnerships to expand the reach of its platform technology.